BLA 761497 · Emerge Bioscience Pte. Ltd.
Garzulys
Insulin Aspart-Fsan · Multidose, Prefilled · Insulin Analog
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 24, 2026
Approved uses
2
Original approval plus efficacy supplements
Registered trials
485
129 Phase 3, 9 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 31, 2026.
Garzulys™ is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Garzulys is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 ).
Mechanism: The primary activity of insulin, including insulin aspart products, is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- GARZULYS · INSULIN ASPART-FSAN 10ML · VIAL, MULTIDOSE · Prescription
- GARZULYS · INSULIN ASPART-FSAN 3ML · PEN, PREFILLED · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Aspart" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) StudyPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00101751 · 4,877 participants · Start Oct 2004 · Primary completion Jun 2006
Drug: biphasic insulin aspart · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Princeton, New Jersey
- A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03689374 · 2,274 participants · Start Oct 1, 2018 · Primary completion Feb 22, 2021
Drug: Semaglutide; Insulin aspart and 1 more · For: Diabetes Mellitus, Type 2
Sites: Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina; Tuzla, Bosnia and Herzegovina · 210 sites in all
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational DiabetesPivotal-lookingRecruiting
Ohio State UniversityAcademic, hospital or other
NCT06445946 · 1,572 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 2029
Drug: Metformin; Insulin · For: Gestational Diabetes Mellitus; Pregnancy, High Risk
Sites: Tuscaloosa, Alabama; Los Angeles, California; San Francisco, California · 26 sites in all
- Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01831765 · 1,290 participants · Start Aug 26, 2013 · Primary completion May 12, 2015
Drug: Faster-acting insulin aspart; insulin detemir and 2 more · For: Diabetes; Diabetes Mellitus, Type 1
Sites: Mobile, Alabama; Tucson, Arizona; Anaheim, California · 191 sites in all
- Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03268005 · 1,264 participants · Start Sep 19, 2017 · Primary completion Jan 7, 2019
Drug: Faster-acting insulin aspart; Insulin aspart and 2 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Concord, California; Fresno, California; Fullerton, California · 167 sites in all
- Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02500706 · 1,108 participants · Start May 4, 2016 · Primary completion Jul 17, 2017
Drug: Faster-acting insulin aspart; insulin aspart and 1 more · For: Diabetes; Diabetes Mellitus, Type 1
Sites: Tucson, Arizona; Concord, California; Encino, California · 152 sites in all
- Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00972283 · 1,006 participants · Start Sep 1, 2009 · Primary completion Oct 28, 2010
Drug: insulin degludec; insulin glargine and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Alexander City, Alabama; Birmingham, Alabama; Goodyear, Arizona · 136 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D, Babazono T, Cailleteau R, et al. · Lancet 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Biosimilars and Novel Insulins.
Ampudia-Blasco FJ · Am J Ther 2020 · Systematic Review
- Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
Billings LK, Andreozzi F, Frederiksen M, et al. · Lancet Diabetes Endocrinol 2025 · Randomized Controlled Trial, Multicenter Study
- Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
Hövelmann U, Engberg S, Heise T, et al. · Diabetes Obes Metab 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure.
Drai RV, Karonova TL, Mayorov AY, et al. · Clin Pharmacol Drug Dev 2022 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Emerge Bioscience Pte. Ltd.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.